Company intelligence / Profile preview

Jesil Pharmaceutical Industries

Minna, Niger State, Nigeria

Ownership: Private
Development stage: Other

Overview

Jesil Pharmaceutical Industries manufactured and marketed "JESIL TETINREX SYRUP", containing paracetamol and diphenhydramine HCl, available in Nigeria for relief of cough symptoms as an OTC product; production capabilities include oral liquids and topical products. GMP reassessment by NAFDAC was satisfactory as of July 2023, indicating continued operations.

Therapeutic areas: ImmunologyNeurologyPulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Jesil Pharmaceutical Industries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jesil Pharmaceutical Industries.

Explore the full profile